MIRA Pharmaceuticals Inc. (MIRA) recently unveiled encouraging preclinical findings from a study on its novel oral ketamine analog, Ketamir-2, tested in a rat model designed to mimic nerve-ligation induced neuropathic pain.
MIRA's stock ended Friday's regular trading session at $1.85, marking a slight decline of $0.02, or 1.07%. However, in after-hours trading, the stock surged by $0.87 or 47.03%.
Per the company's report, administering low oral doses of Ketamir-2 significantly and sustainably reversed neuropathic pain, with effects persisting for 14 and 22 days post-operation.
Notably, the highest dose of Ketamir-2 led to a complete normalization of the pain threshold, effectively achieving a full reversal of neuropathic pain signals.
In comparison, oral ketamine under similar conditions did not result in significant pain relief, underscoring the superior efficacy of Ketamir-2.
The company emphasized that these findings highlight Ketamir-2's potential to revolutionize neuropathic pain treatment and pave the way for its progression into clinical development.
